Similar articles

• Should all CMV infections after bone marrow transplantation be treated?

  Jouet JP, Draoui A, Facon T, Noel-Walter MP, Wattre P, Fenaux P, Dupriez B, Morel P, Bauters F. Jouet JP, et al. Bone Marrow Transplant. 1991;7 Suppl 2:47. Bone Marrow Transplant. 1991. PMID: 1652333 No abstract available.
• CMV prophylaxis in allogeneic BMT with ganciclovir and CMV immune globulin.

  Patton WN, Carter C, Bienz N, Lamb T, Boughton BJ, Franklin IM. Patton WN, et al. Bone Marrow Transplant. 1991;7 Suppl 2:44. Bone Marrow Transplant. 1991. PMID: 1652330 Clinical Trial. No abstract available.
• Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients.

  Meyers JD. Meyers JD. Transplant Proc. 1991 Jun;23(3 Suppl 3):139-42, discussion 142-3. Transplant Proc. 1991. PMID: 1648819 Review. No abstract available.
• Treatment of severe cytomegalovirus infection with ganciclovir and high-dose intravenous immunoglobulin in patients with allogeneic bone marrow transplants. A pilot study.

  Lehn P, Quessar A, Devergie A, Esperou-Bourdeau H, Traineau R, Trédaniel J, Benbunan M, Bussel A, Jolivet I, Mazeron MC, et al. Lehn P, et al. Nouv Rev Fr Hematol (1978). 1990;32(1):17-20. Nouv Rev Fr Hematol (1978). 1990. PMID: 2161510
• [Incidence, therapy and prevention of cytomegalovirus disease after bone marrow transplantation].

  Schuler U, Ehninger G. Schuler U, et al. Med Klin (Munich). 1992 Oct;87 Suppl 1:30-8. Med Klin (Munich). 1992. PMID: 1334220 Review. German. No abstract available.